Is penumbral imaging useful for extending the treatment window for intravenous tissue plasminogen activator?

Annals of Neurology

Volumn 60, Issue 5, 2006, Pages 499-501

  Fisher, Marc ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESMOTEPLASE; FIBRINOLYTIC AGENT; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR;

BRAIN PERFUSION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; EDITORIAL; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT IDENTIFICATION; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; RECANALIZATION; REPERFUSION; TREATMENT INDICATION;

BRAIN; BRAIN ISCHEMIA; CEREBROVASCULAR CIRCULATION; DIFFUSION MAGNETIC RESONANCE IMAGING; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33845346166     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21043     Document Type: Editorial

References (12)

1. Albers GW, Thijs VN, Wechsler L, et al. MRI profiles predict clinical response to early reperfusion: the DEFUSE study. Ann Neurol 2006;60:508-517.
2. Molina CA, Montaner J, Arenillas JF, et al. Differential pattern of tissue plasminogen activator-induced proximal middle cerebral artery recanalization among stroke subtypes. Stroke 2004;35:486-490.
3. Smith WS, Sung G, Starkman S, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005;36:1432-1440.
4. Ribo M, Molina CA, Rovira A, et al. Safety and efficacy of intravenous tissue plasminogen activator stroke treatment in the 3- to 6 hour window using multimodal transcranial Doppler/MRI selection protocol. Stroke 2005;36:602-606.
5. Thomalla G, Schwark C, Sobesky J, et al. Outcome and symptomatic bleeding complications of intravenous thrombolysis with 6 hours in MRI-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS and NINDS tPA trials. Stroke 2006;37:852-858.
6. Hacke W, Albers GW, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66-73.
7. Furlan AJ, Eyding D, Albers GW, et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006;37:1227-1231.
8. Kidwell CS, Alger JR, Saver JL. Beyond mismatch: evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging. Stroke 2003;34:2729-2735.
9. Fehler J, Knudsen K, Kucinski T, et al. Predictors of apparent diffusion coefficient normalization in stroke patients. Stroke 2004;35:514-519.
10. Wintermark M, Sesay M, Barbier E, et al. Comparative overview of brain perfusion techniques. Stroke 2005;36:e83-e99.
11. Shen Q, Fisher M, Sotak CH, Duong TQ. Effects of reperfusion on ADC and CBF pixel-by-pixel dynamics in stroke: characterizing tissue fates using quantitative diffusion and perfusion imaging. J Cereb Blood Flow Metab 2004;24:280-290.
12. Wintermark M, Flanders AE, Velthius B, et al. Perfusion-CT assessment of infarct core and penumbra: receiver operating characteristic curve analysis in 130 patients suspected of hemispheric stroke. Stroke 2006;37:1771-1777.